Lyra Therapeutics, Inc.LYRANASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+101.0%
5Y CAGR+25.3%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+101.0%/yr
Quarterly compound
5Y CAGR
+25.3%/yr
Recent acceleration
Percentile
P92
Near historical high
vs 5Y Ago
3.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 38.66% |
| Q2 2025 | -4138.46% |
| Q1 2025 | 23.53% |
| Q4 2024 | 5.56% |
| Q3 2024 | 75.34% |
| Q2 2024 | -108.57% |
| Q1 2024 | -40.00% |
| Q4 2023 | 7.41% |
| Q3 2023 | 25.00% |
| Q2 2023 | 18.18% |
| Q1 2023 | 2.22% |
| Q4 2022 | -12.50% |
| Q3 2022 | 4.76% |
| Q2 2022 | 54.35% |
| Q1 2022 | 12.38% |
| Q4 2021 | -23.53% |
| Q3 2021 | 0.00% |
| Q2 2021 | -41.67% |
| Q1 2021 | -11.11% |
| Q4 2020 | -10.20% |
| Q3 2020 | 12.50% |
| Q2 2020 | -60.00% |
| Q1 2020 | 38.62% |
| Q4 2019 | 13.60% |
| Q3 2019 | 1.49% |
| Q2 2019 | -17.54% |
| Q1 2019 | 0.00% |